疗效曙光初现,一线治疗前路坎坷——评免疫检测点抑制剂在HER2变异晚期非小细胞肺癌中的应用  

Early Dawn of Curative Effect and Bumpy Road Ahead for First⁃Line Treatment:Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non⁃Small Cell Lung Cancer With HER2 Alterations

作　　者：刘馨屿 任胜祥[1] 孙月丽[2] LIU Xin-yu;REN Sheng-xiang;SUN Yue-li(Department of Medical Oncology,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China;不详)

机构地区：[1]同济大学附属上海市肺科医院肿瘤内科,上海200433 [2]广东省人民医院肿瘤中心、广东省医学科学院,广东省肺癌研究所,广州510080

出　　处：《循证医学》2022年第4期198-201,211,共5页The Journal of Evidence-Based Medicine

摘　　要：1文献来源研究一:Saalfeld FC,Wenzel C,Christopoulos P,et al.Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations[J].J Thorac Oncol,2021,16(11):1952-1958.研究二:Yang G,Yang Y,Liu R,et al.First⁃line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2⁃altered NSCLC:a retrospective real⁃world POLISH study[J].Ther Adv Med Oncol,2022,14:17588359221082339.

关 键 词：HER2 ERBB2 非小细胞肺癌 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]